Drug Status Key

  • Preferred
  • On Formulary
  • Specialist Initiation
  • Shared Care
  • Hospital Only
  • Under Review
  • New on System

2.6.2 Calcium-channel blockers

Notes:

  1. Specify the brand when prescribing a modified release diltiazem preparation (excluding 60mg tablet).
  2. Specify the brand when prescribing a modified release verapamil preparation.
  3. Verapamil is used where there is co-existing paroxysmal supraventricular tachycardia, or atrial fibrillation ±hypertension ± angina.
  4. Verapamil has several significant drug interactions (see BNF for comprehensive list) including:
      β-blockers when asystole, severe hypotension and heart failure may ensue;
      digoxin where the plasma levels of digoxin may be increased, and there is risk of AV block and bradycardia.
  5. Nimodipine is included for the prevention and treatment of ischaemic neurological deficits following subarachnoid haemorrhage.
  6. Although nifedipine has been removed from the formulary, patients currently taking nifedipine obtaining benefit with no adverse effects, should remain on the product and not be switched.

 

Please note, sample information has been entered into Chapters 1 and 2 only and although fairly clinically accurate, it is not guaranteed. The information was entered during April and May 2017 and drugs will have subsequently been randomly added during telephone demonstrations.

Show All

Pack Price
14 tablet
28 tablet £0.79
30 tablet
Pack Price
28 tablet £0.73
30 tablet
Pack Price
100 tablet
28 tablet £1.48
60 tablet
Pack Price
100 tablet
28 tablet
56 tablet £28.20
Pack Price
100 tablet
84 tablet £1.79
Pack Price
5 ampoule
Pack Price
100 tablet
84 tablet £2.03